Ever-Growing USA on MSN2d
Retratutide: Eli Lilly’s Groundbreaking Drug Poised to Transform Obesity and Diabetes Treatment
In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
BioSpace5d
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
BioPharma Dive8d
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Fierce Pharma9d
With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Fierce Healthcare12d
Eli Lilly expands telehealth access to low-cost Zepbound with Teladoc Health, LifeMD tie-ups
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Indianapolis Business Journal12d
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...